Abstract Background: Batroxobin, a defibrinogenating agent used as an adjunctive therapy for sudden sensorineural hearing loss (SSNHL), has an incompletely characterized cardiovascular safety profile. Cases: We report three male patients with SSNHL who developed acute myocardial infarction (AMI) after batroxobin therapy. All three showed a precipitous fibrinogen decline (nadir: 0.48–0.75 g/L). AMI was diagnosed approximately 24–48 h after the final batroxobin dose.